{"id":367,"date":"2014-07-07T18:18:02","date_gmt":"2014-07-07T22:18:02","guid":{"rendered":"http:\/\/blogs.shu.edu\/cancer\/?p=367"},"modified":"2021-07-02T08:51:59","modified_gmt":"2021-07-02T12:51:59","slug":"pd-1-inhibitor-approved-in-asia","status":"publish","type":"post","link":"http:\/\/blogs.shu.edu\/cancer\/2014\/07\/07\/pd-1-inhibitor-approved-in-asia\/","title":{"rendered":"PD-1 inhibitor approved in Asia"},"content":{"rendered":"<p><a title=\"Anti-PD-1 cancer star nivolumab wins world's first regulatory approval\" href=\"http:\/\/www.fiercebiotech.com\/story\/anti-pd-1-cancer-star-nivolumab-wins-worlds-first-regulatory-approval\/2014-07-07\" target=\"_blank\" rel=\"noopener\">Ono Pharmaceuticals <\/a>announced that nivolumab has been approved in Asia. \u00a0It obtained the rights to nivolumab from Medarex in 2005. \u00a0It is approved for use in patients with unresectable melanoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ono Pharmaceuticals announced that nivolumab has been approved in Asia. \u00a0It obtained the rights to nivolumab from Medarex in 2005. \u00a0It is approved for use in patients with unresectable melanoma.<\/p>\n","protected":false},"author":2252,"featured_media":294,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[28],"tags":[89,207,41],"class_list":["post-367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-checkpoint-inhibitors","tag-nivolumab","tag-ono","tag-pd-1"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/users\/2252"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/comments?post=367"}],"version-history":[{"count":2,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/367\/revisions"}],"predecessor-version":[{"id":5010,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/367\/revisions\/5010"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media\/294"}],"wp:attachment":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media?parent=367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/categories?post=367"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/tags?post=367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}